New hope for Tough-to-Treat colon cancer: experimental drug shows promise in early trial
NCT ID NCT05513742
First seen Apr 18, 2026 · Last updated Apr 28, 2026 · Updated 2 times
Summary
This study tested an experimental drug called CTX-009 in 49 adults with metastatic colorectal cancer that had worsened after two or three prior chemotherapy treatments. The goal was to see if the drug could shrink tumors or stop them from growing. Researchers measured how many patients had their tumors shrink or stabilize, and for how long. This is a phase 2 trial, meaning it's still early, but results could lead to a new option for people with advanced colon or rectal cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Florida Cancer Specialists & Research Institute - North
St. Petersburg, Florida, 33705, United States
-
Florida Cancer Specialists & Research Institute - South
Fort Myers, Florida, 33916, United States
-
Genesis Cancer and Blood Institute
Hot Springs, Arkansas, 71913, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
Zangmeister Cancer Center
Columbus, Ohio, 43219, United States
Conditions
Explore the condition pages connected to this study.